Trebananib (formerly known as AMG386) was an investigational recombinant peptide-Fc fusion protein that inhibits tumor angiogenesis by blocking the interaction between Ang1 and 2 and their receptor Tie2 (Figure 1). Here, ANGPT1 is linked to neoplasm.